Cerus Corporation (CERS) on Focus After Trading At 52-Week Highs

March 20, 2018 - By Vivian Currie

Investors sentiment increased to 1.32 in Q3 2017. Its up 0.02, from 1.3 in 2017Q2. It is positive, as 9 investors sold Cerus Corporation shares while 22 reduced holdings. 11 funds opened positions while 30 raised stakes. 57.26 million shares or 0.28% less from 57.42 million shares in 2017Q2 were reported.
Schwab Charles Inv Inc holds 401,735 shares or 0% of its portfolio. Geode Mgmt Lc holds 0% or 913,732 shares in its portfolio. Rhumbline Advisers owns 115,131 shares. Price T Rowe Assocs Inc Md accumulated 0% or 112,000 shares. 560,214 were reported by Renaissance Techs Llc. Moreover, Athena Advsrs Ltd Llc has 0.02% invested in Cerus Corporation (NASDAQ:CERS). Citadel Advsrs Ltd Liability accumulated 0% or 933,089 shares. Us Financial Bank De owns 38,362 shares for 0% of their portfolio. Stoneridge Ltd Com owns 50,734 shares or 0.02% of their US portfolio. Budros Ruhlin & Roe reported 0.04% in Cerus Corporation (NASDAQ:CERS). Premier Asset Management Limited Liability Corp has invested 0.08% in Cerus Corporation (NASDAQ:CERS). Cannell Peter B & Company Incorporated invested in 0.01% or 105,000 shares. Envestnet Asset Mgmt Incorporated accumulated 5,377 shares. Deutsche Bancshares Ag reported 1.64M shares. Swiss Bancorp reported 0% stake.

Since March 10, 2018, it had 1 buying transaction, and 5 selling transactions for $597,723 activity. On Saturday, March 10 the insider Benjamin Richard J sold $18,328. 17,766 shares were sold by Greenman William Mariner, worth $87,795. Another trade for 150,011 shares valued at $773,199 was made by CORASH LAURENCE M on Monday, March 12. Menard Chrystal sold $22,793 worth of stock or 4,610 shares. Shares for $23,151 were sold by Moore Carol on Saturday, March 10.

The stock of Cerus Corporation (NASDAQ:CERS) hit a new 52-week high and has $6.18 target or 7.00 % above today’s $5.78 share price. The 6 months bullish chart indicates low risk for the $748.42 million company. The 1-year high was reported on Mar, 20 by Barchart.com. If the $6.18 price target is reached, the company will be worth $52.39M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 5.58% or $0.31 during the last trading session, reaching $5.78. About 729,672 shares traded. Cerus Corporation (NASDAQ:CERS) has declined 40.83% since March 20, 2017 and is downtrending. It has underperformed by 57.53% the S&P500.

Analysts await Cerus Corporation (NASDAQ:CERS) to report earnings on May, 2. They expect $-0.12 EPS, up 33.33 % or $0.06 from last year’s $-0.18 per share. After $-0.10 actual EPS reported by Cerus Corporation for the previous quarter, Wall Street now forecasts 20.00 % negative EPS growth.

Cerus Corporation (NASDAQ:CERS) Ratings Coverage

Among 5 analysts covering Cerus (NASDAQ:CERS), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Cerus has $8 highest and $4.0 lowest target. $5.75’s average target is -0.52% below currents $5.78 stock price. Cerus had 11 analyst reports since August 11, 2015 according to SRatingsIntel. The company was maintained on Wednesday, August 19 by BTIG Research. On Tuesday, August 11 the stock rating was downgraded by Zacks to “Buy”. The company was maintained on Monday, October 30 by Robert W. Baird. Cowen & Co maintained it with “Buy” rating and $6.0 target in Thursday, October 5 report. On Friday, May 26 the stock rating was maintained by BTIG Research with “Buy”. The company was downgraded on Thursday, December 17 by Wedbush. The firm earned “Buy” rating on Wednesday, January 24 by Robert W. Baird. The stock of Cerus Corporation (NASDAQ:CERS) has “Buy” rating given on Thursday, March 8 by Cantor Fitzgerald. The stock of Cerus Corporation (NASDAQ:CERS) has “Buy” rating given on Wednesday, June 7 by Cantor Fitzgerald. The firm has “Buy” rating given on Monday, January 8 by Cantor Fitzgerald.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company has market cap of $748.42 million. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. It currently has negative earnings. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.